Spinraza

Indications

Spinraza is specifically indicated for the treatment of spinal muscular atrophy (SMA). It is approved for use in patients of all ages, including infants, children, and adults.

Understanding Spinal Muscular Atrophy

SMA is a rare, inherited neuromuscular disorder caused by a deficiency of a specific protein necessary for the survival of motor neurons. Without enough of this protein, the nerve cells that control muscle movement shrink and eventually die, leading to:

• Progressive muscle weakness
• Loss of motor skills, such as sitting, standing, or walking
• Difficulties with breathing and swallowing in severe cases

Spinraza is used to treat various forms of the condition, regardless of the specific SMA type or the age at which symptoms first appeared. It is administered directly into the fluid surrounding the spinal cord to reach the affected nerve cells and help improve motor function.

Targeting the SMN Protein

Spinal muscular atrophy (SMA) is caused by a deficiency of survival motor neuron (SMN) protein. This protein is essential for the health of motor neurons, which are the nerve cells in the spinal cord that control muscle movement. When these protein levels are too low, motor neurons can become damaged or die, leading to muscle weakness and wasting.

The Role of the SMN2 Gene

Humans have a backup gene called SMN2 that can also produce the SMN protein. However, in most people, the SMN2 gene contains a splicing error that causes it to produce mostly non-functional, shortened protein. Only a small fraction of the protein made by this backup gene is useful to the body.

How Spinraza Works

Spinraza is an antisense oligonucleotide, which is a short string of synthetic genetic material. It is designed to bind to the messenger RNA (mRNA) produced by the SMN2 gene. By binding to a specific spot, it corrects the splicing error, allowing the SMN2 gene to produce more full-length, functional SMN protein.

By increasing the amount of functional protein available to the central nervous system, Spinraza helps to:

• Support nerve health: It helps maintain the motor neurons that are necessary for muscle function.
• Preserve muscle function: By protecting the nerves, the medicine aims to slow the progression of muscle weakness and improve motor milestones.

Common Side Effects

The most frequently reported side effects of Spinraza include:

• Lower or upper respiratory tract infections
• Constipation
• Headache
• Back pain
• Vomiting

In infants and children, other common side effects may include ear infections, nasal congestion, and teething pain.

Serious Side Effects

While less common, some patients may experience serious complications. Seek medical attention immediately if you notice signs of:

• Bleeding or bruising: Spinraza may lower platelet counts, which can increase the risk of bleeding.
• Kidney damage: Some patients have experienced kidney toxicity. Healthcare providers typically monitor urine protein levels and blood work during treatment to check kidney health.
• Severe allergic reactions: Symptoms may include rash, swelling, or difficulty breathing.

Procedure-Related Effects

Because Spinraza is administered via an injection into the fluid surrounding the spinal cord (intrathecal injection), some side effects are related to the procedure itself. These can include back pain or a specific type of headache that occurs after a lumbar puncture.

Bleeding and Coagulation Risks

Spinraza may increase the risk of bleeding complications. Some patients treated with this medication have experienced low blood platelet counts (thrombocytopenia) or abnormalities in blood clotting. Healthcare providers typically perform blood tests to check platelet counts and coagulation factors before starting treatment and before each subsequent dose.

Kidney Toxicity

Kidney damage, also known as renal toxicity, has been observed with medications in the same class as Spinraza. This may manifest as high levels of protein in the urine. Monitoring kidney function through urine protein testing is recommended before each dose to detect potential issues early.

Procedure-Related Risks

Spinraza is administered via an injection into the fluid surrounding the spinal cord (intrathecal injection). This procedure, known as a lumbar puncture, carries its own set of risks, including:

• Headache
• Back pain
• Nausea or vomiting
• Infection or bleeding at the injection site

In some cases, especially in patients with scoliosis or other spinal abnormalities, ultrasound or other imaging may be used to guide the injection safely.

Pregnancy and Breastfeeding

There is limited data regarding the use of Spinraza during pregnancy or while breastfeeding. The potential risks to a fetus or nursing infant are not fully known, and the decision to use the medication in these situations involves weighing the benefits against potential risks.

Pregnancy

There are no adequate or well-controlled studies on the use of Spinraza in pregnant women. In animal studies involving mice and rabbits, no evidence of harm to the fetus or birth defects was observed, even at doses higher than those typically used in humans. However, animal research does not always predict how a drug will affect human pregnancy.

If you are pregnant or planning to become pregnant, it is important to discuss the potential risks and benefits of treatment with your healthcare provider. They can help determine if the clinical need for the medication outweighs the potential risks to the fetus.

Breastfeeding

It is not known whether Spinraza passes into human breast milk or if it has any effect on a nursing infant or milk production. In animal studies, the drug was detected in the milk of lactating mice. When considering breastfeeding while on this medication, the developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for the drug and any potential adverse effects on the breastfed child.

Available Forms

Spinraza is supplied as a preservative-free solution for intrathecal administration. It is provided in the following form:

• Single-dose vial: A liquid solution intended for a single injection into the space around the spinal cord.

FDA Approval and Indication

The U.S. Food and Drug Administration (FDA) approved Spinraza on December 23, 2016. It is indicated for the treatment of spinal muscular atrophy (SMA) in both children and adults. Spinraza was the first medication approved by the FDA to treat this rare genetic condition.

Regulatory History

During its development, Spinraza received several special designations from the FDA to expedite its availability, including:

• Fast Track: A process designed to facilitate the development and review of drugs for serious conditions with unmet medical needs.
• Priority Review: An expedited review process for drugs that offer significant improvements in safety or effectiveness.
• Orphan Drug Designation: A status granted to drugs intended for the treatment of rare diseases.

Safety and Monitoring

There are currently no Boxed Warnings or Risk Evaluation and Mitigation Strategies (REMS) required for Spinraza. However, the FDA-approved labeling includes warnings regarding the risk of low blood platelet counts (thrombocytopenia) and kidney damage (renal toxicity). Healthcare providers are advised to perform blood and urine tests before starting treatment and before each dose to monitor for these potential issues.

Factors Affecting Cost

Spinraza is a specialty medication used to treat spinal muscular atrophy (SMA). Because it is administered as an intrathecal injection—meaning it is injected directly into the fluid surrounding the spinal cord—the total cost of treatment typically includes several components:

• Medication Price: The cost of the drug itself.
• Clinical Administration: Fees for the healthcare professional performing the procedure.
• Facility Charges: Costs associated with the hospital or clinic where the injection is performed.
• Supportive Care: Potential costs for imaging (such as ultrasound or X-ray) used to guide the needle, or sedation if required.

Insurance and Support

Most insurance plans, including private insurance and government programs like Medicare and Medicaid, provide coverage for Spinraza. However, patients often need to meet specific criteria, and healthcare providers must usually obtain prior authorization from the insurance company before starting treatment.

Financial assistance programs may be available through the manufacturer to help eligible patients with out-of-pocket expenses. Patients and caregivers should consult with their insurance provider and medical team to determine the specific coverage details and explore available support options.